Revance Therapeutics Company Profile (NASDAQ:RVNC)

About Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics logoRevance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RVNC
  • CUSIP: N/A
  • Web: www.revance.com
Capitalization:
  • Market Cap: $623.62 million
  • Outstanding Shares: 30,273,000
Average Prices:
  • 50 Day Moving Avg: $20.89
  • 200 Day Moving Avg: $19.89
  • 52 Week Range: $12.35 - $24.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.01
  • P/E Growth: -0.47
Sales & Book Value:
  • Annual Revenue: $300,000.00
  • Price / Sales: 2,078.75
  • Book Value: $5.93 per share
  • Price / Book: 3.47
Profitability:
  • EBIDTA: ($85,040,000.00)
  • Net Margins: -28,187.33%
  • Return on Equity: -37.31%
  • Return on Assets: -33.87%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 11.92%
  • Quick Ratio: 11.92%
Misc:
  • Average Volume: 180,982 shs.
  • Beta: 1.7
  • Short Ratio: 19.71
 

Frequently Asked Questions for Revance Therapeutics (NASDAQ:RVNC)

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) issued its earnings results on Tuesday, May, 9th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.10. The firm earned $0.08 million during the quarter, compared to the consensus estimate of $0.07 million. Revance Therapeutics had a negative return on equity of 37.31% and a negative net margin of 28,187.33%. The company's quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.71) EPS. View Revance Therapeutics' Earnings History.

Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?

5 brokerages have issued 1 year target prices for Revance Therapeutics' stock. Their forecasts range from $22.00 to $55.00. On average, they expect Revance Therapeutics' share price to reach $39.20 in the next year. View Analyst Ratings for Revance Therapeutics.

What are analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:

  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (5/9/2017)
  • 2. Aegis analysts commented, "We spoke with management this morning to which they mentioned they do not expect a material increase in research and development costs in association with the trial site expansion." (5/1/2017)

Who are some of Revance Therapeutics' key competitors?

Who owns Revance Therapeutics stock?

Revance Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (11.80%), Wellington Management Group LLP (7.13%), Bank of New York Mellon Corp (6.20%), Vanguard Group Inc. (2.96%), Canada Pension Plan Investment Board (1.99%) and Goldman Sachs Group Inc. (1.87%). Company insiders that own Revance Therapeutics stock include Arthur Peter Bertolino, Curtis Ruegg and L Daniel Browne. View Institutional Ownership Trends for Revance Therapeutics.

Who sold Revance Therapeutics stock? Who is selling Revance Therapeutics stock?

Revance Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Wellington Management Group LLP, Morgan Stanley, Wells Fargo & Company MN, Suffolk Capital Management LLC, Credit Suisse AG, Rothschild Asset Management Inc. and ProShare Advisors LLC. Company insiders that have sold Revance Therapeutics stock in the last year include Curtis Ruegg and L Daniel Browne. View Insider Buying and Selling for Revance Therapeutics.

Who bought Revance Therapeutics stock? Who is buying Revance Therapeutics stock?

Revance Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Vanguard Group Inc., Victory Capital Management Inc., Acadian Asset Management LLC, JPMorgan Chase & Co. and Geode Capital Management LLC. View Insider Buying and Selling for Revance Therapeutics.

How do I buy Revance Therapeutics stock?

Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Revance Therapeutics stock cost?

One share of Revance Therapeutics stock can currently be purchased for approximately $20.60.

Analyst Ratings

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $39.20 (90.29% upside)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017AegisReiterated RatingBuy$28.00 -> $36.00LowView Rating Details
8/5/2016Brean CapitalReiterated RatingHoldN/AView Rating Details
6/14/2016SunTrust Banks, Inc.Lower Price TargetBuy$46.00 -> $22.00N/AView Rating Details
6/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$54.00 -> $35.00N/AView Rating Details
6/14/2016GuggenheimReiterated RatingBuy$55.00N/AView Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/10/2015William BlairReiterated RatingBuy$59.00N/AView Rating Details
6/6/2015BMO Capital MarketsReiterated RatingOutperform$24.00 -> $35.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Revance Therapeutics (NASDAQ:RVNC)
Earnings by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Earnings History by Quarter for Revance Therapeutics (NASDAQ:RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.84)($0.94)$0.07 million$0.08 millionViewListenView Earnings Details
2/27/2017Q416($0.84)($0.95)$0.07 million$0.08 millionViewListenView Earnings Details
11/3/2016Q316($0.89)($0.64)$0.08 million$0.08 millionViewN/AView Earnings Details
8/4/2016Q216($0.86)($0.88)$0.06 million$0.80 millionViewN/AView Earnings Details
5/9/2016Q1($0.83)($0.71)$0.08 million$0.08 millionViewListenView Earnings Details
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q415($0.84)($0.71)$0.15 million$0.08 millionViewN/AView Earnings Details
5/13/2015Q1($0.69)($0.65)$0.15 million$0.08 millionViewListenView Earnings Details
3/2/2015($0.53)($0.60)$0.08 million$0.08 millionViewN/AView Earnings Details
11/12/2014Q314($0.69)($0.60)$0.08 millionViewN/AView Earnings Details
8/12/2014($0.68)($0.69)$0.08 millionViewN/AView Earnings Details
5/13/2014Q1 14($0.87)($1.93)$0.16 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
2017 EPS Consensus Estimate: ($3.80)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.85)($0.80)($0.83)
Q2 20172($0.99)($0.98)($0.99)
Q3 20172($1.02)($1.02)($1.02)
Q4 20172($0.99)($0.95)($0.97)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Revance Therapeutics (NASDAQ:RVNC)
Insider Ownership Percentage: 31.15%
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/25/2017L Daniel BrowneCEOSell12,000$19.78$237,360.00View SEC Filing  
12/28/2016L Daniel BrowneCEOSell12,000$20.94$251,280.00View SEC Filing  
11/25/2016L Daniel BrowneCEOSell12,000$17.92$215,040.00View SEC Filing  
10/26/2016L Daniel BrowneCEOSell12,000$14.85$178,200.00View SEC Filing  
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Revance Therapeutics (NASDAQ:RVNC)
Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
Source:
DateHeadline
seekingalpha.com logoRevance Therapeutics (RVNC) Presents On Phase 2 Cervical Dystonia 24-Week Results - Slideshow
seekingalpha.com - May 23 at 7:01 PM
americanbankingnews.com logoRevance Therapeutics Inc (RVNC) Stock Rating Reaffirmed by Aegis
www.americanbankingnews.com - May 19 at 9:36 PM
americanbankingnews.com logoRevance Therapeutics Inc (RVNC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 7:30 PM
finance.yahoo.com logoRevance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial
finance.yahoo.com - May 19 at 12:32 PM
finance.yahoo.com logoETFs with exposure to Revance Therapeutics, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 6:50 PM
finance.yahoo.com logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : May 15, 2017
finance.yahoo.com - May 15 at 9:32 AM
americanbankingnews.com logoSunTrust Banks Weighs in on Revance Therapeutics Inc's Q2 2017 Earnings (RVNC)
www.americanbankingnews.com - May 15 at 7:28 AM
finance.yahoo.com logoRevance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 11:00 PM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Revance Therapeutics Inc Issued By William Blair (RVNC)
www.americanbankingnews.com - May 12 at 8:34 AM
americanbankingnews.com logoRevance Therapeutics Inc (RVNC) Issues Quarterly Earnings Results, Misses Expectations By $0.10 EPS
www.americanbankingnews.com - May 10 at 6:58 PM
finance.yahoo.com logoEdited Transcript of RVNC earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 11:06 AM
finance.yahoo.com logoInvestor Network: Revance Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 7:10 PM
finance.yahoo.com logoRevance Releases First Quarter 2017 Results
finance.yahoo.com - May 9 at 7:10 PM
finance.yahoo.com logoRevance reports 1Q loss
finance.yahoo.com - May 9 at 7:10 PM
finance.yahoo.com logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : May 5, 2017
finance.yahoo.com - May 5 at 7:57 PM
americanbankingnews.com logoRevance Therapeutics (RVNC) Earns Daily Coverage Optimism Score of 0.01
www.americanbankingnews.com - May 3 at 2:12 PM
americanbankingnews.com logoRevance Therapeutics Inc (RVNC) Earns "Buy" Rating from Aegis
www.americanbankingnews.com - May 1 at 4:14 PM
finance.yahoo.com logoRevance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
finance.yahoo.com - May 1 at 10:01 AM
americanbankingnews.com logoRevance Therapeutics (RVNC) Earns Daily News Sentiment Score of 0.19
www.americanbankingnews.com - April 30 at 8:23 AM
americanbankingnews.com logoFavorable Media Coverage Extremely Likely to Impact Revance Therapeutics (RVNC) Stock Price
www.americanbankingnews.com - April 26 at 12:30 PM
finance.yahoo.com logoRevance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017
finance.yahoo.com - April 25 at 6:40 PM
americanbankingnews.com logoRevance Therapeutics Inc (RVNC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 24 at 9:44 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Likely to Impact Revance Therapeutics (RVNC) Share Price
www.americanbankingnews.com - April 23 at 9:17 PM
finance.yahoo.com logoRevance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : April 20, 2017
finance.yahoo.com - April 20 at 7:42 PM
americanbankingnews.com logoVery Favorable News Coverage Very Unlikely to Affect Revance Therapeutics (RVNC) Stock Price
www.americanbankingnews.com - April 19 at 10:29 AM
finance.yahoo.com logoRevance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : April 19, 2017
finance.yahoo.com - April 19 at 9:29 AM
nasdaq.com logoCommit To Buy Revance Therapeutics At $17.50, Earn 13.3% Annualized Using Options
www.nasdaq.com - April 7 at 12:22 PM
americanbankingnews.com logoRevance Therapeutics Inc (RVNC) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 29 at 12:55 PM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 15 at 8:53 AM
seekingalpha.com logoRevance Therapeutics (RVNC) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 8 at 7:52 PM
finance.yahoo.com logoRevance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
finance.yahoo.com - March 7 at 9:21 AM
finance.yahoo.com logoREVANCE THERAPEUTICS, INC. Financials
finance.yahoo.com - March 4 at 7:33 PM
finance.yahoo.com logoRevance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting
finance.yahoo.com - March 3 at 8:13 AM
us.rd.yahoo.com logoEdited Transcript of RVNC earnings conference call or presentation 27-Feb-17 9:30pm GMT
us.rd.yahoo.com - March 2 at 12:55 AM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - February 28 at 7:18 PM
us.rd.yahoo.com logoRevance Releases Fourth Quarter and Full Year 2016 Results
us.rd.yahoo.com - February 27 at 4:27 PM
biz.yahoo.com logoQ4 2016 Revance Therapeutics Inc Earnings Release - After Market Close
biz.yahoo.com - February 27 at 9:25 AM
finance.yahoo.com logoRevance to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 22 at 7:49 PM
finance.yahoo.com logoRevance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017
finance.yahoo.com - February 16 at 7:18 PM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 8 at 11:44 PM
uk.finance.yahoo.com logoBELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
us.rd.yahoo.com - January 27 at 2:34 AM
us.rd.yahoo.com logoRevance Presents Clinical Data for RT002 Injectable at TOXINS 2017
us.rd.yahoo.com - January 18 at 9:03 PM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - January 12 at 9:01 PM
streetinsider.com logoRevance Therapeutics (RVNC) Offers FY17 Outlook - StreetInsider.com
www.streetinsider.com - January 8 at 12:20 AM
streetinsider.com logoRevance Therapeutics (RVNC) Offers FY17 Outlook
www.streetinsider.com - January 6 at 3:23 AM
us.rd.yahoo.com logoRevance Provides Clinical Milestones and Financial Outlook for 2017
us.rd.yahoo.com - January 6 at 3:23 AM
us.rd.yahoo.com logo4:18 pm Revance Therapeutics expects cash burn for 2017 to be in the range of $102 to $112 mln; provides clinical updates
us.rd.yahoo.com - January 6 at 3:23 AM
biz.yahoo.com logoREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - January 6 at 3:23 AM
finance.yahoo.com logoRevance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial
finance.yahoo.com - December 12 at 7:44 PM
finance.yahoo.com logo4:06 pm Revance Therapeutics announces positive interim results from its U.S. Phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults
finance.yahoo.com - December 12 at 7:44 PM

Social

Chart

Revance Therapeutics (RVNC) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff